Surprise! Clovis Oncology Nabs Early OK

The FDA has given a green light to Clovis Oncology s NASDAQ CLVS ovarian cancer drug Rubraca Its approval offers new hope to ovarian cancer patients who have seen their disease progress despite prior treatment and it positions Clovis Oncology to compete against